Clinical efficacy of teriflunomide over a fixed 2-year duration in the TOWER study
{{output}}
Patients enrolled in the phase 3 TOWER study (NCT00751881) of teriflunomide had variable treatment durations (48-173 weeks). This has led to challenges when interpreting results in the context of other phase 3 trials of disease-modifying therapies for multiple... ...
